clinical trial endpoint

Staffaroni, Adam M.; Bajorek, Lynn; Casaletto, Kaitlin B.; Cobigo, Yann; Goh, Sheng-Yang M.; Wolf, Amy; Heuer, Hilary W.; Elahi, Fanny M.; Ljubenkov, Peter A.; Dever, Reilly; Kornak, John; Appleby, Brian; Bove, Jessica; Bordelon, Yvette; Brannelly, Patrick; Brushaber, Danielle; Caso, Christina; Coppola, Giovanni; Dheel, Christina; Dickerson, Bradford C.; Dickinson, Susan; Dominguez, Sophia; Domoto-Reilly, Kimiko; Faber, Kelly; Ferrall, Jessica; Fields, Julie A.; Fishman, Ann; Fong, Jamie; Foroud, Tatiana; Forsberg, Leah K.; Gavrilova, Ralitza; Gearhart, Debra; Ghazanfari, Behnaz; Ghoshal, Nupur; Goldman, Jill; Graff-Radford, Jonathan; Graff-Radford, Neill; Grant, Ian; Grossman, Murray; Haley, Dana; Hsiung, Ging-Yuek; Huey, Edward D.; Irwin, David J.; Jones, David T.; Jones, Lynne; Kantarci, Kejal; Karydas, Anna; Kaufer, Daniel I.; Kerwin, Diana R.; Knopman, David S.; Kraft, Ruth; Kremers, Walter K.; Kukull, Walter A.; Litvan, Irene; Lucente, Diane; Lungu, Codrin; Mackenzie, Ian R.; Maldonado, Miranda; Manoochehri, Masood; McGinnis, Scott M.; McKinley, Emily; Mendez, Mario F.; Miller, Bruce L.; Multani, Namita; Onyike, Chiadi; Padmanabhan, Jaya; Pantelyat, Alex; Pearlman, Rodney; Petrucelli, Len; Potter, Madeline; Rademakers, Rosa; Ramos, Eliana Marisa; Rankin, Katherine P.; Rascovsky, Katya; Roberson, Erik D.; Rogalski, Emily; Sengdy, Pheth; Shaw, Leslie M.; Syrjanen, Jeremy; Tartaglia, M. Carmela; Tatton, Nadine; Taylor, Joanne; Toga, Arthur; Trojanowski, John Q.; Weintraub, Sandra; Wang, Ping; Wong, Bonnie; Wszolek, Zbigniew; Boxer, Adam L.; Boeve, Brad F.; Kramer, Joel H.; Rosen, Howard J.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

clinical trial endpoint

Published Date:

January 2020

Source:

Alzheimers Dement. 16(1):11-21

Language:

English

Public Access Version Available on: January 01, 2021, 12:00 AM

Please check back on the date listed above.

Details:

Alternative Title:

Alzheimers Dement

Personal Author:

Staffaroni, Adam M. ; Bajorek, Lynn ; Casaletto, Kaitlin B. ; Cobigo, Yann ; Goh, Sheng-Yang M. ; ... More ▼

Description:

Introduction:

Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression.

Methods:

Ninety-three mutation carriers with no symptoms or minimal/questionable symptoms (MAPT, n = 31; GRN,n = 28; C9orf72,n = 34; Clinical Dementia Rating scale plus NACC FTLD Module <1) and 78 noncarriers enrolled through Advancing Research and Treatment in Frontotemporal Lobar Degeneration/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects studies completed the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH-EXAMINER) and the UDS neuropsychological battery. Linear mixed-effects models were used to identify group differences in cognition at baseline and longitudinally. We examined associations between cognition, clinical functioning, and magnetic resonance imaging volumes.

Results:

NIH-EXAMINER scores detected baseline and differences in slopes between carriers and noncarriers, even in carriers with a baseline Clinical Dementia Rating scale plus NACC FTLD Module = 0. NIH-EXAMINER declines were associated with worsening clinical symptoms and brain volume loss.

Discussion:

The NIH-EXAMINER is sensitive to cognitive changes in presymptomatic familial FTLD and is a promising surrogate endpoint.

Subject:

[+]

Pubmed ID:

31914230

Pubmed Central ID:

PMC6842665

Document Type:

Journal Article

Funding:

Biogen/International ; K24 AG045333/AG/NIA NIH HHS/United States ; U24 AG021886/AG/NIA NIH HHS/United States ; P01 AG017586/AG/NIA NIH HHS/United States ; Genentech/International ; ... More ▼

Collection(s):

CDC Public Access

Main Document Checksum:

[+]

Supporting Files:

No Additional Files

No Related Documents.

You May Also Like:

Priorities for CMV vaccine development

Personal Author:

Krause, Philip R.; Bialek, Stephanie R.; Boppana, Suresh B.; Griffiths, Paul D.; Laughlin, Catherine A.; Ljungman, Per; Mocarski, Edward S.; Pass, Robert F.; Read, Jennifer S.; Schleiss, Mark R.; Plotkin, Stanley A.;

Published Date:

Oct 13 2013

Source:

Vaccine. 32(1):4-10

Description:

A multidisciplinary meeting addressed priorities related to development of vaccines against cytomegalovirus (CMV), the cause of congenital CMV (cCMV) disease and of serious disease in the immunocompromised. Participants discussed optimal uses of a CM...

File Type:

[PDF - 129.52 KB]
Media matters: Modeling the impact of solid media performance on tuberculosis trial sample size requirements

Personal Author:

Johnson, Matthew G.; Stout, Jason E.; Benator, Debra A.; Whitworth, William C.; Holland, David P.;

Published Date:

May 2016

Source:

Int J Tuberc Lung Dis. 20(5):600-604.

Description:

SettingTwo-month solid media culture conversion is a commonly used (if suboptimal) endpoint for phase 2 tuberculosis treatment trials.Objective and DesignTo model the effect of solid media performance characteristics (sensitivity and contamination ra...

File Type:

[PDF - 257.92 KB]
Estimation of HIV Incidence in a Large, Community-Based, Randomized Clinical Trial: NIMH Project Accept (HIV Prevention Trials Network 043)

Personal Author:

Laeyendecker, Oliver; Piwowar-Manning, Estelle; Fiamma, Agnes; Kulich, Michal; Donnell, Deborah; Bassuk, Deb; Mullis, Caroline E.; Chin, Craig; Swanson, Priscilla; Hackett, John; Clarke, William; Marzinke, Mark; Szekeres, Greg; Gray, Glenda; Richter, Linda; Alexandre, Michel W.; Chariyalertsak, Suwat; Chingono, Alfred; Celentano, David D.; Morin, Stephen F.; Sweat, Michael; Coates, Thomas; Eshleman, Susan H.;

Published Date:

Jul 11 2013

Source:

PLoS One. 2013; 8(7).

Description:

BackgroundNational Institute of Mental Health Project Accept (HIV Prevention Trials Network [HPTN] 043) is a large, Phase III, community-randomized, HIV prevention trial conducted in 48 matched communities in Africa and Thailand. The study interventi...

File Type:

[PDF - 412.12 KB]
DEFENS - Drug Exposure Feedback and Education for Nurses’ Safety: study protocol for a randomized controlled trial

Personal Author:

Friese, Christopher R; Mendelsohn-Victor, Kari; Wen, Bo; Sun, Duxin; Sutcliffe, Kathleen; Yang, James J; Ronis, David L; McCullagh, Marjorie C;

Corporate Authors:

For the DEFENS Study Investigators

Published Date:

Apr 17 2015

Source:

Trials. 16.

Description:

BackgroundThree decades of research findings have documented the health effects of handling hazardous drugs. Oncology nurses are vulnerable due to frequent administration of antineoplastics, low adherence to equipment use, reported barriers to use, a...

File Type:

[PDF - 899.53 KB]
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance

Personal Author:

Lienhardt, Christian; Vernon, Andrew A.; Cavaleri, Marco; Nambiar, Sumati; Nahid, Payam;

Published Date:

September 06 2019

Source:

PLoS Med. 2019; 16(9)

Description:

Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.

File Type:

[PDF - 444.45 KB]